1-17 of 17
Rhine R. Shen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Sattva S. Neelapu, Julio C. Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Andrew Lee, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4868.
https://doi.org/10.1182/blood-2023-174914
Published: 2023
Journal Articles

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Mike Mattie, Melanie Grosso, Aurelie Auguste, Denis Arnaud, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Jenny Nater, Rhine R. Shen, Jerome Galon
Journal: Blood
Blood (2023) 142 (Supplement 1): 226.
https://doi.org/10.1182/blood-2023-187574
Published: 2023
Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2120.
https://doi.org/10.1182/blood-2023-174681
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 106.
https://doi.org/10.1182/blood-2023-174273
Published: 2023
Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick Stiff, Ian W. Flinn, Umar Farooq, Andre H. Goy, Peter A. McSweeney, Javier Munoz, Tanya Siddiqi, Julio C. Chavez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jenny J. Kim, Yan Zheng, Frederick L. Locke
Journal: Blood
Blood (2023) 141 (19): 2307–2315.
https://doi.org/10.1182/blood.2022018893
Published: 2023
Includes: Supplemental data
Journal Articles

Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Mark B. Leick, Seunghun Han, Kathleen M.E. Gallagher, Harrison Silva, Grace Martin, Sabrina Camp, Hoyin Chu, Riaz Gillani, Michael C. Kann, Bryan D. Choi, Rebecca Larson, Merle Phillips, Tamina Kienka, Stefanie R. Bailey, Charlotte Graham, Christopher R. Reilly, Max Jan, Elba Gonzalez, Nora K. Horick, Justin Budka, Simone Filosto, Rhine R. Shen, Eliezer Van Allen, Saud H AlDubayan, Marcela V. Maus
Journal: Blood
Blood (2022) 140 (Supplement 1): 646–647.
https://doi.org/10.1182/blood-2022-166322
Published: 2022
Journal Articles

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9320–9322.
https://doi.org/10.1182/blood-2022-158097
Published: 2022
Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R. Shen, Harry Miao, Jenny Kim, Tom van Meerten
Journal: Blood
Blood (2022) 140 (Supplement 1): 10399–10401.
https://doi.org/10.1182/blood-2022-156117
Published: 2022
Journal Articles

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jiali Yan, Qinghua Song, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10380–10383.
https://doi.org/10.1182/blood-2022-156120
Published: 2022
Journal Articles

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Matthew J. Frigault, Kathleen M.E. Gallagher, Marc Wehrli, Betsy Valles, Keagan Casey, Kevin Lindell, Michael Trailor, Hana Cho, Jami L. Brown, Nora K. Horick, Justin Chou, Rhine R. Shen, Simone Filosto, Adrian Bot, Marcela V. Maus
Journal: Blood
Blood (2021) 138 (Supplement 1): 2814.
https://doi.org/10.1182/blood-2021-146927
Published: 2021
Journal Articles

Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

Qinghua Song, Tao Hu, Sattva S. Neelapu, Frederick L. Locke, Caron Jacobson, David B. Miklos, Olalekan O. Oluwole, Marie José Kersten, Max Topp, Jenny J. Kim, Kanwarjit Singh, Jorge Andrade, Lei Huang, Allen Xue, Marco Schupp, Myrna Nahas, Rhine R. Shen, Adrian Bot
Journal: Blood
Blood (2021) 138 (Supplement 1): 2833.
https://doi.org/10.1182/blood-2021-148580
Published: 2021
Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John M. Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Jenny J. Kim, Yan Zheng, Rhine R. Shen, Saran Vardhanabhuti, Tom Van Meerten
Journal: Blood
Blood (2021) 138 (Supplement 1): 2832.
https://doi.org/10.1182/blood-2021-147403
Published: 2021
Journal Articles

Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products

Irene Scarfò, Kathleen M.E. Gallagher, Mark B. Leick, Michael C. Kann, Justin Budka, Bharat Sowrirajan, Kim Nguyen, Rhine R. Shen, Adrian Bot, Marcela V. Maus
Journal: Blood
Blood (2021) 138 (Supplement 1): 3849.
https://doi.org/10.1182/blood-2021-146941
Published: 2021
Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Caron Jacobson, Frederick L. Locke, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick Stiff, Ian W. Flinn, Umar Farooq, Andre H. Goy, Javier Muñoz, Tanya Siddiqi, Rhine R. Shen, Adrian Bot, Jinghui Dong, Kanwarjit Singh, Clare Spooner, Roshan Karalliyadda, Jenny J. Kim, Yan Zheng, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1764.
https://doi.org/10.1182/blood-2021-148078
Published: 2021
Journal Articles

Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas

Matthew J. Frank, David W. Dawson, Steven J. Bensinger, Jason S. Hong, Wendy M. Knosp, Lizhong Xu, Cynthia E. Balatoni, Eric L. Allen, Rhine R. Shen, Dafna Bar-Sagi, Gail R. Martin, Michael A. Teitell
Journal: Blood
Blood (2009) 113 (11): 2478–2487.
https://doi.org/10.1182/blood-2008-05-156943
Published: 2009
Includes: Supplemental data
Journal Articles

Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation

Rhine R. Shen, David O. Ferguson, Mathilde Renard, Katrina K. Hoyer, Unkyu Kim, Xingpei Hao, Frederick W. Alt, Robert G. Roeder, Herbert C. Morse, III, Michael A. Teitell
Journal: Blood
Blood (2006) 108 (6): 1991–1998.
https://doi.org/10.1182/blood-2006-02-001354
Published: 2006
Includes: Supplemental data
Journal Articles

TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4 + CD56 + blastic tumors of skin

Brief Report
Marco Herling, Michael A. Teitell, Rhine R. Shen, L. Jeffrey Medeiros, Dan Jones
Journal: Blood
Blood (2003) 101 (12): 5007–5009.
https://doi.org/10.1182/blood-2002-10-3297
Published: 2003